CLPTM1L and neoplasm: Control mice had an average increase in tumor load of 2.45-fold at day 42, while 102-5 anti-CLPTM1L-treated mice had an average of 0.90-fold relative tumor load at day 42 (T-test p < 0.005) (Paired t-test across time points, p = 0.001).